Systems and methods for identifying cosmetic agents for hair/scalp care compositions

• US 9,920,357 B2
• Filed: 06/06/2013
• Issued: 03/20/2018
• Est. Priority Date: 06/06/2012
• Status: Active Grant

• Current Assignee: The Procter & Gamble Company
• Original Assignee: The Procter & Gamble Company
• Inventors: Youngquist, Robert Scott, Xu, Jun, Binder, Robert Lloyd, Hu, Ping, Dicolandrea, Teresa, Dawson, Thomas Larry, Howard, Brian Wilson
• Primary Examiner(s): Lin, Jerry
• Application Number:
  US13/911,698
• Publication Number:
  US 20130331342A1
• Time in Patent Office: 1,748 Days
• Field of Search: 702 19
• CPC Class Codes: C12Q 1/6837 using probe arrays or probe chips C12Q1/6874 takes precedence
• CPC Class Codes: G16B 20/00 ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
• CPC Class Codes: G16B 20/20 Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
• CPC Class Codes: G16B 25/00 ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
• CPC Class Codes: G16B 25/10 Gene or protein expression profiling; Expression-ratio estimation or normalisation

Abstract

Provided are methods and systems for determining functional relationships between a cosmetic agent and a hair biology condition of interest. Also provided are methods and systems for identifying cosmetic agents that affect a hair biology condition, as well as the use of agents identified by such methods and systems for the preparation of cosmetic compositions, personal care products, or both.

Claims

1. A method for constructing a data architecture for use in identifying connections between perturbagens and genes associated with one or more cosmetic hair biology conditions and preparing a hair/scalp care composition, comprising:

(a) providing a gene expression profile for a control human fibroblast cell;

(b) generating a gene expression profile for a human fibroblast cell exposed to at least one perturbagen by extracting a biological sample from the exposed cell and subjecting the biological sample to microarray analysis via a microarray scanner;

(c) identifying genes differentially expressed in response to the at least one perturbagen by comparing the gene expression profiles of (a) and (b);

(d) creating an ordered list comprising identifiers representing the differentially expressed genes, wherein the identifiers are ordered according to the differential expression of the genes;

(e) storing the ordered list as a fibroblast instance on at least one computer readable medium; and

(f) constructing a data architecture of stored fibroblast instances by repeating (a) through (e), wherein the at least one perturbagen of step (a) is different for each fibroblast instance;

(g) providing a gene expression profile for a control human keratinocyte cell;

(h) generating a gene expression profile for a human keratinocyte cell exposed to at least one perturbagen by extracting a biological sample from the exposed cell and subjecting the biological sample to microarray analysis via a microarray scanner;

(i) identifying genes differentially expressed in response to the at least one perturbagen by comparing the gene expression profiles of (g) and (h);

(j) creating an ordered list comprising identifiers representing the differentially expressed genes, wherein the identifiers are ordered according to the differential expression of the genes identified in (i);

(k) storing the ordered list created in step (j) as a keratinocyte instance on the at least one computer readable medium;

(l) constructing a data architecture of stored keratinocyte instances by repeating (g) through (k), wherein the at least one perturbagen of step (h) is different for each keratinocyte instance;

(m) querying the data architectures of stored fibroblast and keratinocyte instances with at least one hair biology-relevant gene expression signature, wherein querying comprises comparing the at least one hair biology-relevant gene expression signature to each stored fibroblast and keratinocyte instance, wherein the hair biology-relevant gene expression signature represents genes differentially expressed in association with the at least one hair biology condition;

(n) assigning a connectivity score to each of the instances; and

(o) preparing a hair/scalp care composition comprising at least one perturbagen, wherein the connectivity score of the instance associated with the at least one perturbagen has a negative correlation.

2. A method according to claim 1, comprising using a programmable computer to perform one or more of steps (c), (d), (e) and (f).

3. A method according to claim 1, wherein the ordered list comprises the ordered list of identifiers in association with a numerical ranking for the identifier corresponding to its rank in the ordered list.

4. A method according to claim 1, wherein the biological sample comprises mRNA.

5. A method according to claim 1, wherein the microarray is a global microarray or a specific microarray, wherein the specific microarray comprises oligonucleotides which hybridize to genes corresponding to a gene expression signature for a cellular phenotype.

6. A method according to claim 1, wherein the step of constructing the data architecture of stored fibroblast instances by repeating steps (a) through (e) comprises repeating steps (a) through (e) for between about 50 and about 50,000 instances.

7. A method according to claim 6, wherein the step of constructing the data architecture of stored fibroblast instances comprises repeating steps (a) through (e) for between about 1000 and about 20,000 instances.

8. A method according to claim 1, wherein the at least one perturbagen is a cosmetic agent.

9. A method according to claim 1, wherein each of the different perturbagens is a cosmetic agent.

10. A method according to claim 1, wherein the identifiers are selected from the group consisting of gene names, gene symbols, microarray probe set ID values, and combinations thereof.

11. A method according to claim 1, wherein the ordered list is arranged so that an identifier associated with a most up-regulated gene is positioned at the top of the ordered list and an identifier associated with a most down-regulated gene is positioned at the bottom of the ordered list.

12. A method according to claim 11, wherein the ordered list of each fibroblast and keratinocyte instance is arranged so that an identifier associated with each gene that is not differentially expressed is positioned between the identifier associated with the most up-regulated gene and the identifier associated with the most down-regulated gene.

13. A method according to claim 1, wherein each fibroblast and keratinocyte instance comprises between about 1,000 and about 50,000 identifiers.

14. A method according to claim 1, wherein each fibroblast and keratinocyte instance comprises metadata for the at least one perturbagen associated with the instance.

15. A method according to claim 1, wherein the at least one perturbagen of step (b) is the same as the at least one perturbagen of step (h).

16. A method according to claim 1, wherein the at least one perturbagen is a botanical.

17. A method according to claim 16, wherein the botanical is derived from one or more of a root, stem, bark, leaf, seed, or fruit of a plant.

18. A method according to claim 1, wherein the at least one perturbagen is selected from the group consisting of a vitamin compound, a sugar amine, a phytosterol, hexamidine, a hydroxy acid, a ceramide, an amino acid, and a polyol.

19. A method according to claim 18, wherein the vitamin compound is selected from the group consisting of a vitamin B3 compound, a vitamin B5 compound, a vitamin B6 compound, a vitamin B9 compound, a vitamin A compound, a vitamin C compound, a vitamin E compound, and derivatives and combinations thereof.

20. A method according to claim 18, wherein the vitamin compound is selected from the group consisting of retinol, retinyl esters, niacinamide, folic acid, panthenol, ascorbic acid, tocopherol, and tocopherol acetate.

21. A method according to claim 1, wherein the comparison of the at least one hair biology-relevant gene expression signature to each stored fibroblast and keratinocyte instance is performed by a programmable computer.

22. A method according to claim 1, wherein the at least one hair biology condition is selected from the group consisting of follicular miniaturization (alopecia), dermal papilla activation, hair density modification, chronogenetic alopecia, senile alopecia, hair diameter modification, loss of hair pigmentation, hair thinning, hair loss, fragile hair, curl or lack of curl;

and combinations thereof.

23. A method according to claim 1, wherein the at least one hair biology-relevant gene expression signature is constructed by a method comprising (i) identifying genes having up-regulated expression in the at least one hair biology condition when compared to a control;

(ii) identifying genes having down-regulated expression in the at least one hair biology condition when compared to a control;

(iii) creating one or more gene expression signature lists associated with the at least one hair biology-relevant gene expression signature comprising identifiers corresponding to a plurality of the genes identified in (i) and (ii); and

storing the one or more gene expression signature lists on the at least one computer readable medium.

24. A method according to claim 23, wherein the number of genes having up-regulated expression in the at least one hair biology condition is between about 10 and about 400, and the number of genes down-regulated in the at least one hair biology condition is between about 10 and about 400.

25. A method according to claim 24 wherein the identifiers for between about 80% and about 100% of the up-regulated genes are set forth as in Table B and wherein identifiers for between about 80% and about 100% of the down-regulated genes are set forth in Table A.

26. A method according to claim 1, wherein the identifiers representing the genes identified in (i) and (ii) are selected from the group consisting of gene names, gene symbols, and microarray probe set ID values.

27. A method according to claim 23, wherein the one or more gene expression signature lists comprises a first list representing a plurality of the up-regulated genes identified in (i) and a second list representing a plurality of down-regulated genes identified in (ii).

28. A method according to claim 23, wherein at least one hair sample is taken from a human subject exhibiting the at least one hair biology condition, a biological sample is extracted from the hair sample, and a gene expression profile of the at least one hair sample is generated prior to at least one of the steps (i) and (ii).

29. A method according to claim 28, wherein the at least one human subject is between the ages of about 18 and about 80.

30. A method according to claim 28, wherein the hair sample comprises cells from a vertex of a head of the human subject.

31. A method according to claim 1, wherein a plurality of connectivity scores represents a positive correlation and a plurality of the connectivity scores represents a negative correlation.

32. A method according to claim 1, wherein the connectivity score has a value between +2 and −

2.

33. A method for constructing a data architecture for use in identifying connections between cosmetic perturbagens and genes associated with cosmetically improving hair biology and preparing a hair/scalp care composition, comprising:

(a) providing a gene expression profile for a control fibroblast human cell;

(b) generating a gene expression profile for a human fibroblast cell exposed to at least one perturbagen by extracting a biological sample from the exposed cell and subjecting the biological sample to microarray analysis via a microarray scanner;

(c) identifying genes differentially expressed in response to at least one perturbagen by comparing the gene expression profiles of (a) and (b);

(d) creating an ordered list comprising identifiers representing the differentially expressed genes, wherein the identifiers are ordered according to the differential expression of the genes;

(e) storing the ordered list as a fibroblast instance on at least one computer readable medium;

(f) constructing a data architecture of stored instances by repeating (a) through (e), wherein the at least one perturbagen of step (b) is different qualitatively or quantitatively for each instance;

(g) repeating steps (a) through (f) for a control human keratinocyte cell and human keratinocyte cells;

(h) constructing a data architecture incorporating both the fibroblast and the keratinocyte instances;

(i) querying the data architecture of stored instances with at least one hair biology relevant gene expression signature, wherein querying comprises comparing the hair biology-relevant gene expression signature to each stored cell instance, wherein the hair biology-relevant expression signature represents genes differentially expressed in a human tissue affected with a cosmetic hair biology condition or genes differentially expressed in cells treated with at least one benchmark agent having known efficacy in treating a cosmetic hair condition;

(j) assigning a connectivity score to each of the instances; and

(k) preparing a hair/scalp care composition comprising at least one perturbagen, wherein the connectivity score of the instance associated with the at least one perturbagen has a negative correlation.

34. A method according to claim 33, comprising using a programmable computer to perform one or more steps (c), (d), (e), and (f).

35. A method according to claim 33, wherein the ordered list comprises the ordered list of identifiers in association with a numerical ranking for the identifier corresponding to its rank in the ordered list.

36. A method according to claim 33, wherein the biological sample comprises mRNA.

37. A method according to claim 33, wherein the microarray is a global microarray or a specific microarray, wherein the specific microarray comprises oligonucleotides which hybridize to genes according to a gene expression signature for a cellular phenotype.

38. A method according to claim 33, wherein the step of constructing the data architecture of stored instances by repeating steps (a) through (e) comprises repeating steps (a) through (e) for between about 50 and about 50,000 instances.

39. A method according to claim 33, wherein the step of constructing the data architecture of stored instances comprises repeating steps (a) through (e) for between about 1000 and 20,000 instances.

40. A method according to claim 33, wherein the at least one perturbagen comprises an agent modifying hair follicle cycling.

41. The method of claim 40 wherein modifying hair follicle cycling comprises transitioning dermal papilla cells from a resting telogen stage to a growing anagen stage.

42. The method of claim 33 wherein prior to step (a), induced pluripotent stem cells (IPSC) are induced into the human cell line selected from the group consisting of fibroblast and keratinocyte cell lines.

43. The method according to claim 33 further comprising

(l) repeating steps (a) through (f) for a control human melanocyte cell and human melanocyte cells and/or repeating steps (a) through (f) for a control human dermal papilla cell and human dermal papilla cells;

and

(m) constructing a data architecture incorporating all instances.